NEW YORK--(BUSINESS WIRE)--June 26, 2006--OMRIX Biopharmaceuticals, Inc. (NASDAQ: OMRI - News) announced today that patient enrollment in the multi-center, Phase III pivotal trial for the Company’s Thrombin stand-alone product candidate has been completed. OMRIX’s Thrombin stand-alone, which is derived from human plasma, is designed to provide effective hemostasis (control of bleeding) without the risk of adverse reactions associated with the use of bovine-sourced hemostats. OMRIX’s Thrombin will be available in a frozen liquid form making it ready for immediate use without the need for re-constitution. While the product will have a two year stability, it can be stored liquid in the operating room refrigerator for 30 days. Currently, the only stand-alone thrombin product available in the U.S. is a bovine-based lyophilized product.
